Oliver S. Eng

Oliver S. Eng

Auto-generated profile, based on publicly available information

Oliver S. Eng

Department of Surgery, University of California Irvine, Orange, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2020 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
Daniel VT CatenacciDaniel VT Catenacci
Daniel VT Catenacci
SMStephanie Moya
Stephanie Moya
SLSamantha Lomnicki
Samantha Lomnicki
LCLeah M. Chase
Leah M. Chase
BPBryan F. Peterson
Bryan F. Peterson
HKHedy L. Kindler
Hedy L. Kindler
The one-year and median overall survival (mOS) rates of advanced gastroesophageal adenocarcinomas (GEA) are ∼50% and <12 months, respectively. Baseline spatial and temporal molecular heterogeneity of targetable alterations may be a cause of failure of targeted/immunooncologic therapies. This heterogeneity, coupled with infrequent incidence of some biomarkers, has resulted in stalled therapeutic progress. We hypothesized that a personalized treatment strategy, applied at first diagnosis then serially over up to three treatment lines using monoclonal antibodies combined with optimally sequenced chemotherapy, could contend with these hurdles. This was tested using a novel clinical expansion-platform type II design with a survival primary endpoint. Of 68 patients by intention-to-treat, the one-year survival rate was 66% and mOS was 15.7 months, meeting the primary efficacy endpoint (one-sided P = 0.0024). First-line response rate (74%), disease control rate (99%), and median progression-free survival (8.2 months) were superior to historical controls. The PANGEA strategy led to improved outcomes warranting a larger randomized study.Significance: This study highlights excellent outcomes achieved by individually optimizing chemotherapy, biomarker profiling, and matching of targeted therapies at baseline and over time for GEA. Testing a predefined treatment strategy resulted in improved outcomes versus historical controls. Therapeutic resistance observed in correlative analyses suggests that dual targeted inhibition may be beneficial.This article is highlighted in the In This Issue feature, p. 211

19 November 2019 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
LXLai Xue
Lai Xue
NHNeil H. Hyman
Neil H. Hyman
KTKiran K. Turaga
Kiran K. Turaga
OEOliver S. Eng
Oliver S. Eng

1 June 2021 in Surgical Oncology
Verified
Journal Article
Closed access
JWJason T. Wiseman
Jason T. Wiseman
SASherif Raafat Zikry Abdel-Misih
Sherif Raafat Zikry Abdel-Misih
EBEliza W. Beal
Eliza W. Beal
MZMohammad Y. Zaidi
Mohammad Y. Zaidi
CSCharles A. Staley
Charles A. Staley
JCJordan Cloyd
Jordan Cloyd

10 March 2019 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
OEOliver S. Eng
Oliver S. Eng
KTKiran K. Turaga
Kiran K. Turaga

26 October 2020 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
MWMichael G. White
Michael G. White
JSJefree J. Schulte
Jefree J. Schulte
LXLai Xue
Lai Xue
YBYaniv Berger
Yaniv Berger
DSDarryl Schuitevoerder
Darryl Schuitevoerder
OEOliver S. Eng
Oliver S. Eng
Programmed death-ligand 1 (PD-L1) expression has been described in patients with malignant peritoneal mesothelioma (MPM), but treatment strategies utilising immune checkpoint inhibition are yet to be defined. Here, we examine levels of PD-L1 expression in MPM patients treated with systemic and/or intraperitoneal chemotherapy using tissue from patient tumour biopsies or resections at multiple time points. We found the mean PD-L1 expression was higher in those with a germline mutation and/or those with a higher somatic mutation burden. Moreover, PD-L1 expression was lower in patients who had received prior chemotherapy as compared to the treatment-naive cohort. Twenty patients who received chemotherapy, either systemic and/or peritoneal, between PD-L1 measurements showed marked heterogeneity. Six (30%) patients demonstrated upregulation of PD-L1, while eight (40%) demonstrated downregulation. Heterogeneity in PD-L1 expression in MPM before and after cytotoxic therapies may present an additional consideration when initiating immune checkpoint inhibition in this rare and challenging disease.

20 May 2020 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
CVCharles C. Vining
Charles C. Vining
FIFrancisco Izquierdo
Francisco Izquierdo
OEOliver S. Eng
Oliver S. Eng
KTKiran K. Turaga
Kiran K. Turaga